Skip to Main Content

Rise and shine. Another busy day is on the way. And it is also a noisy one here on the sunny and breezy Pharmalot campus, thanks to the return of the local water company and its sewer project. We plan to cope by quaffing cups of stimulation. Feel free to join us for whatever reason motivates you. And now, on with the show. As always, here are some tidbits. Hope your day goes well and you conquer the world …

French prosecutors have started an involuntary manslaughter investigation in connection with a trial in which one volunteer died and five others were hospitalized, Le Figaro reports. Although investigations by other authorities indicated the drug given trial participants was not adulterated and the study protocol was followed, prosecutors want to know if criminal mistakes were made or whether the tragedy was the result of clinical risks involved.


GlaxoSmithKline’s Moncef Slaoui, who runs the vaccines division and has spent nearly 30 years with the drug maker, plans to retire next year, Bloomberg News notes. The decision comes as Glaxo chairman Philip Hampton searches for a new chief executive to replace Andrew Witty, who is leaving next March amid consternation over the strategic direction he has taken the  company.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.